Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial

IMPORTANCE: Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non–small cell lung cancer (NSCLC). OBJECTIVE: To compare ensartinib with crizotinib among patients with advanced ALK-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Horn, Leora, Wang, Ziping, Wu, Gang, Poddubskaya, Elena, Mok, Tony, Reck, Martin, Wakelee, Heather, Chiappori, Alberto A., Lee, Dae Ho, Breder, Valeriy, Orlov, Sergey, Cicin, Irfan, Cheng, Ying, Liu, Yunpeng, Fan, Yun, Whisenant, Jennifer G., Zhou, Yi, Oertel, Vance, Harrow, Kim, Liang, Chris, Mao, Li, Selvaggi, Giovanni, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414368/
https://www.ncbi.nlm.nih.gov/pubmed/34473194
http://dx.doi.org/10.1001/jamaoncol.2021.3523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414368/
https://www.ncbi.nlm.nih.gov/pubmed/34473194
http://dx.doi.org/10.1001/jamaoncol.2021.3523

Ejemplares similares